ADVERTISEMENT

Taming the Beast

Krysti Hughett shares her experience as a breast cancer survivor and advocate.  

BY KATHY LATOUR
PUBLISHED SUNDAY, DECEMBER 6, 2009
Krysti Hughett listens intently to the woman on the other end of the phone. From her side of the conversation, it’s clear—there is one more breast cancer survivor now living in Hughett’s home city of Indianapolis, Indiana. She reassures the woman and then offers to have someone from the Young Survival Coalition office, where Hughett is a resource specialist, to go with the woman to the doctor.

It’s a 24/7 job for Hughett, and one she embraces with the enthusiasm of a zealot despite dealing with her own ongoing treatment for lung metastases. Diagnosed with stage 4 bilateral inflammatory breast cancer in March 2005, Hughett, 45, was told, until the day she was diagnosed, that the rash on both her breasts was not breast cancer. It made sense to Hughett, who was convinced that the rash was a reaction to a new feather mattress her husband bought a month before. 

“There was no lump, and a mammogram and sonogram three days before diagnosis showed nothing,” she says. “I was a medical consumer who had followed my breast [exams] since age 20 when I had a benign lump—but I was willing to believe the medical professionals.” 

It was a young family internist who prompted Hughett to push for a diagnosis, setting her up with a surgeon while eight core biopsies were being analyzed. Hughett says the surgeon didn’t think it was breast cancer, but conceded that he had no idea what he was looking at and suggested she go to his mentor and teacher Robert Goulet, MD, at the Indiana University Melvin and Bren Simon Cancer Center. 

“Dr. Goulet knew by looking at it that it was inflammatory breast cancer,” Hughett says. 

From there things moved quickly. After four weeks of chemotherapy, Hughett had a bilateral mastectomy. The cancer continued to confound doctors by coming back as triple negative, and then showing as HER2-positive in later pathology. Scans also showed multiple spots on her lungs, meaning the cancer was stage 4. 

It was a shock for Hughett, the mother of three daughters—the youngest only 6. 

She immediately began preoperative chemotherapy, and had a rush, she says, when she realized she was sitting in the same chemo chair that Lance Armstrong used when he got his chemo from Lawrence Einhorn, MD, at Indiana University. Then she began researching her condition. 

“Two weeks after surgery, I met Ginny Mason, the executive director of the Inflammatory Breast Cancer Research Foundation, who was doing a meeting in Indianapolis,” Hughett says. “I walked in and met all these inflammatory women, and it was amazing.” 

Hughett says she dived right into the information, saying her motto has always been, “better the beast I know than the one I don’t.” 

Since then Hughett has advocated for herself by seeking out three clinical trials that have kept her lung mets stable. She jokes that she comes to SABCS to shop for her next clinical trial. 

“I am a clinical trial junky,” she says. 

ADVERTISEMENT
Related Articles
Weighing the Risks and Benefits of Tamoxifen as Chemoprevention in High-Risk Women
BY CHRISTINA IZZO
A new study has found that while the breast cancer prevention drug tamoxifen’s benefits outweigh its risks, the drug isn’t right for all women.
Success Fuels Researcher's Dreams of Helping Patients With Breast Cancer
Every day, breast cancer researcher Edith Perez sets her mind on finding better treatments for the disease and conducting research aimed at improving patients' lives.
Hope vs. Acceptance: The Metastatic Cancer See-Saw
Those of us living with metastatic cancer ride a see-saw between hope and acceptance.
Ovarian Suppression Emerges as Option for Younger, Premenopausal Breast Cancer Patients
BY JASON M. BRODERICK
Women with hormone receptor-positive breast cancer who remained premenopausal after receiving chemotherapy had a lower risk of disease recurrence when adding ovarian suppression to adjuvant Aromasin, according to results from the phase 3 SOFT trial.
Several Cancer Therapies Up for FDA Review in 2015
BY ANITA T. SHAFFER
The Food and Drug Administration’s calendar for making decisions on new cancer drugs and indications is taking shape for 2015, and the clock is ticking on at least 13 applications for novel agents and new therapeutic settings for existing drugs.
Related Videos
Breast Oncologist Beth Overmoyer Explains Results of Ovarian Suppression
Beth Overmoyer, a breast oncologist at Dana-Farber Cancer Institute, speaks on the results of the SOFT trial and its potential impact on young women with hormone receptor-positive breast cancer.
SABCS: Debu Tripathy Discusses Hormonal Therapy Advances in Breast Cancer
Debu Tripathy reports on recent studies involving hormone therapy in estrogen receptor-positive breast cancer.
Follow Up Study Data Draws Attention to Benefit, Side Effects of Adjuvant Chemotherapy in Breast Cancer
Debu Tripathy,editor-in-chief of CURE magazine, explains the importance of chemotherapy studies presented at the 2014 San Antonio Breast Cancer Symposium, including new data on the impact of side effects.
Recent Publications
  • photo
    photo
    photo
    photo
    photo
  • photo
    photo
    photo
    photo
    photo
ADVERTISEMENT
$auto_registration$